GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » VioQuest Pharmaceuticals Inc (OTCPK:VOQP) » Definitions » ROE %

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) ROE % : 0.00% (As of Jun. 2008)


View and export this data going back to . Start your Free Trial

What is VioQuest Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. VioQuest Pharmaceuticals's annualized net income for the quarter that ended in Jun. 2008 was $-4.52 Mil. VioQuest Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Jun. 2008 was $-6.18 Mil. Therefore, VioQuest Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2008 was N/A%.

The historical rank and industry rank for VioQuest Pharmaceuticals's ROE % or its related term are showing as below:

VOQP's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -43.845
* Ranked among companies with meaningful ROE % only.

VioQuest Pharmaceuticals ROE % Historical Data

The historical data trend for VioQuest Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

VioQuest Pharmaceuticals ROE % Chart

VioQuest Pharmaceuticals Annual Data
Trend Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -951.89 -174.39 -253.43 -180.20 -

VioQuest Pharmaceuticals Quarterly Data
Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2,701.64 - - - -

Competitive Comparison of VioQuest Pharmaceuticals's ROE %

For the Biotechnology subindustry, VioQuest Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


VioQuest Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, VioQuest Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where VioQuest Pharmaceuticals's ROE % falls into.



VioQuest Pharmaceuticals ROE % Calculation

VioQuest Pharmaceuticals's annualized ROE % for the fiscal year that ended in Dec. 2007 is calculated as

ROE %=Net Income (A: Dec. 2007 )/( (Total Stockholders Equity (A: Dec. 2006 )+Total Stockholders Equity (A: Dec. 2007 ))/ count )
=-10.892/( (2.841+-4.484)/ 2 )
=-10.892/-0.8215
=N/A %

VioQuest Pharmaceuticals's annualized ROE % for the quarter that ended in Jun. 2008 is calculated as

ROE %=Net Income (Q: Jun. 2008 )/( (Total Stockholders Equity (Q: Mar. 2008 )+Total Stockholders Equity (Q: Jun. 2008 ))/ count )
=-4.524/( (-6.685+-5.671)/ 2 )
=-4.524/-6.178
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Jun. 2008) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


VioQuest Pharmaceuticals  (OTCPK:VOQP) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2008 )
=Net Income/Total Stockholders Equity
=-4.524/-6.178
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.524 / 0)*(0 / 0.9375)*(0.9375 / -6.178)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*N/A
=ROA %*Equity Multiplier
=N/A %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2008 )
=Net Income/Total Stockholders Equity
=-4.524/-6.178
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-4.524 / 0) * (0 / -4.112) * (-4.112 / 0) * (0 / 0.9375) * (0.9375 / -6.178)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= N/A * 0 * N/A % * 0 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Jun. 2008) net income data. The Revenue data used here is four times the quarterly (Jun. 2008) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


VioQuest Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of VioQuest Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 2287, Minneapolis, MN, USA, 55402
Website
VioQuest Pharmaceuticals Inc is a biopharmaceutical company focused on the acquisition, development and commercialization of clinical stage drug therapies targeting both the molecular basis of cancer and side effects of cancer treatment.
Executives
Mark D Dacko director, officer: CFO and Secretary 800 NICOLLET MALL SUITE 2690, MINNEAPOLIS MN 55402
Christopher P. Schnittker officer: V.P. & Chief Financial Officer 29 EMMONS DRIVE, SUITE C-10, PRINCETON NJ 08540
Brian Lenz officer: CFO and Treasurer 65 COMMERCE WAY, HACKENSACK NJ 07601
Lau Johnson Yiu Nam director
Michael Weiser director C/O SPACES, SUITE 265, 3350 VIRGINIA STREET, MIAMI FL 33133
Stephen Rocamboli director, officer: Secretary C/OPARMOUNT CAPITAL, 787 SEVENTH AVE 48TH FL, NEW YORK NY 10019
Daniel E Greenleaf director, officer: President and CEO C/O NABI BIO PHARMACEUTICALS, 5800 PARK OF COMMERCE BLVD., N.W., BOCA RATON FL 33487
Lester E Lipschutz 10 percent owner WOLF BLOCK SCHORR AND SOLIS COHEN, 1650 ARCH STREET, PHILADELPHIA PA 19103
David M Tanen director TWO RIVER GROUP HOLDINGS, LLC., 689 FIFTH AVENUE, NEW YORK NY 10022

VioQuest Pharmaceuticals (VioQuest Pharmaceuticals) Headlines

No Headlines